Acta Pharmaceutica, Vol. 59 No. 1, 2009.
Original scientific paper
https://doi.org/10.2478/v10007-009-0008-9
Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging
AMIR R. JALILIAN
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
NIMA ROSTAMPOUR
; Department of Medical Physics, School of Medicine, University of Medical Sciences, Hamadan, Iran
PEJMAN ROWSHANFARZAD
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
KAMALEDDIN SHAFAII
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
MOHSEN KAMALI-DEHGHAN
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
MEHDI AKHLAGHI
; Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran
Abstract
[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu]ATSM) was prepared using in house-made diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2 produced via the natZn(p,x)61Cu (180 μA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method. [61Cu]ATSM radiochemical purity was >98%, as shown by HPLC and RTLC methods. [61Cu]ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.
Keywords
radiopharmaceuticals; copper-61; [61Cu]ATSM; hypoxia; positron emission tomography; fibrosarcoma; imaging
Hrčak ID:
31929
URI
Publication date:
1.3.2009.
Visits: 2.672 *